肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

成人急性淋巴细胞白血病诊疗规范 （2018年版）

2018-12-13 中华人民共和国国家卫生健康委员会 中华人民共和国国家卫生健康委员会官网

成人急性淋巴细胞白血病诊疗规范

急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL），是一种常见的恶性血液病，生物学特征多样而临床异质性很大，以骨髓和淋巴组织中不成熟淋巴细胞的异常增殖和聚集为特点。ALL占所有白血病的15％，约占急性白血病的30%~40%。发病率在美国白人中为1.5/10万，黑人为0.8/10万；男女之比为1.4:1。我国1986年白血病流行病学调查研究显示我国的ALL发病率为

中文标题：

成人急性淋巴细胞白血病诊疗规范 （2018年版）

发布机构：

中华人民共和国国家卫生健康委员会

发布日期：

2018-12-13

简要介绍：

急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL），是一种常见的恶性血液病，生物学特征多样而临床异质性很大，以骨髓和淋巴组织中不成熟淋巴细胞的异常增殖和聚集为特点。ALL占所有白血病的15％，约占急性白血病的30%~40%。发病率在美国白人中为1.5/10万，黑人为0.8/10万；男女之比为1.4:1。我国1986年白血病流行病学调查研究显示我国的ALL发病率为0.69/10万。美国统计资料显示75%的患者<15岁，发病高峰在3~7岁，10岁以后发病率随年龄增长逐渐下降，但50岁以后发病率又略有上升。成人ALL的中位年龄30~40岁。通常男性比女性稍多见。ALL包括B-ALL及T-ALL，其中B-ALL中20%～30%患者染色体伴（9；22）（q34；q11.2）/BCR-ABL1重现性遗传学异常，称为Ph+ALL。 

拓展指南：与急性淋巴细胞白血病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=成人急性淋巴细胞白血病诊疗规范 （2018年版）)] GetToolGuiderByIdResponse(projectId=1, id=d3c9c1c001680a9d, title=成人急性淋巴细胞白血病诊疗规范 （2018年版）, enTitle=, guiderFrom=中华人民共和国国家卫生健康委员会官网, authorId=null, author=, summary=急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL），是一种常见的恶性血液病，生物学特征多样而临床异质性很大，以骨髓和淋巴组织中不成熟淋巴细胞的异常增殖和聚集为特点。ALL占所有白血病的15％，约占急性白血病的30%~40%。发病率在美国白人中为1.5/10万，黑人为0.8/10万；男女之比为1.4:1。我国1986年白血病流行病学调查研究显示我国的ALL发病率为, cover=, journalId=null, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Thu Dec 13 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL），是一种常见的恶性血液病，生物学特征多样而临床异质性很大，以骨髓和淋巴组织中不成熟淋巴细胞的异常增殖和聚集为特点。ALL占所有白血病的15％，约占急性白血病的30%~40%。发病率在美国白人中为1.5/10万，黑人为0.8/10万；男女之比为1.4:1。我国1986年白血病流行病学调查研究显示我国的ALL发病率为0.69/10万。美国统计资料显示75%的患者<15岁，发病高峰在3~7岁，10岁以后发病率随年龄增长逐渐下降，但50岁以后发病率又略有上升。成人ALL的中位年龄30~40岁。通常男性比女性稍多见。ALL包括B-ALL及T-ALL，其中B-ALL中20%～30%患者染色体伴（9；22）（q34；q11.2）/BCR-ABL1重现性遗传学异常，称为Ph+ALL。 </div> <div><br> </div>拓展指南：<strong>与<font color="red">急性淋巴细胞白血病</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=fa7ce1c0016620fe" title="2018 北美专家共识建议：成人急性淋巴细胞白血病可测量残留病评估和管理" target="_blank">2018 北美专家共识建议：成人急性淋巴细胞白血病可测量残留病评估和管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=7a5571c001660ef5" title="2018 EWALL/EBMT立场声明：造血干细胞移植治疗成人费城染色体阴性急性淋巴细胞白血病首次缓解" target="_blank">2018 EWALL/EBMT立场声明：造血干细胞移植治疗成人费城染色体阴性急性淋巴细胞白血病首次缓解</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e07051c00165a1ea" title="儿童急性淋巴细胞白血病诊疗规范（2018版）" target="_blank">儿童急性淋巴细胞白血病诊疗规范（2018版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=96e6d1c001516e49" title="NCCN临床实践指南：急性淋巴细胞白血病（2017.V5）" target="_blank">NCCN临床实践指南：急性淋巴细胞白血病（2017.V5）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=64b4c1c00151583f" title="2017 日本造血和淋巴组织肿瘤指南：急性淋巴细胞白血病／成淋巴细胞性淋巴瘤" target="_blank">2017 日本造血和淋巴组织肿瘤指南：急性淋巴细胞白血病／成淋巴细胞性淋巴瘤</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E6%80%A5%E6%80%A7%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E7%99%BD%E8%A1%80%E7%97%85" target="_blank">有关急性淋巴细胞白血病更多指南</a></ul>, tagList=[TagDto(tagId=84821, tagName=成人急性淋巴细胞白血病), TagDto(tagId=540, tagName=诊疗规范)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11380, appHits=981, showAppHits=35, pcHits=7621, showPcHits=5932, likes=106, shares=52, comments=9, approvalStatus=1, publishedTime=Wed Dec 26 21:33:21 CST 2018, publishedTimeString=2018-12-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Dec 26 21:33:21 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 06:55:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=成人急性淋巴细胞白血病诊疗规范 （2018年版）)])
成人急性淋巴细胞白血病诊疗规范 （2018年版）
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1219908, encodeId=048b1219908a6, content=太受用了！👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Mon May 16 08:26:30 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999194, encodeId=a6f89991948b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dd75194442, createdName=1472396fm10暂无昵称, createdTime=Tue Jul 13 20:37:46 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926282, encodeId=1afa92628250, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cf4759545, createdName=142f8dc2m65暂无昵称, createdTime=Mon Feb 22 08:05:41 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916336, encodeId=795c9163360c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:33:31 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916333, encodeId=dae6916333c7, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:31:51 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2022-05-16 妙医生

    太受用了！👍🏻

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1219908, encodeId=048b1219908a6, content=太受用了！👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Mon May 16 08:26:30 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999194, encodeId=a6f89991948b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dd75194442, createdName=1472396fm10暂无昵称, createdTime=Tue Jul 13 20:37:46 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926282, encodeId=1afa92628250, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cf4759545, createdName=142f8dc2m65暂无昵称, createdTime=Mon Feb 22 08:05:41 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916336, encodeId=795c9163360c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:33:31 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916333, encodeId=dae6916333c7, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:31:51 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2021-07-13 1472396fm10暂无昵称

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1219908, encodeId=048b1219908a6, content=太受用了！👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Mon May 16 08:26:30 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999194, encodeId=a6f89991948b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dd75194442, createdName=1472396fm10暂无昵称, createdTime=Tue Jul 13 20:37:46 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926282, encodeId=1afa92628250, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cf4759545, createdName=142f8dc2m65暂无昵称, createdTime=Mon Feb 22 08:05:41 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916336, encodeId=795c9163360c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:33:31 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916333, encodeId=dae6916333c7, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:31:51 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2021-02-22 142f8dc2m65暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1219908, encodeId=048b1219908a6, content=太受用了！👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Mon May 16 08:26:30 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999194, encodeId=a6f89991948b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dd75194442, createdName=1472396fm10暂无昵称, createdTime=Tue Jul 13 20:37:46 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926282, encodeId=1afa92628250, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cf4759545, createdName=142f8dc2m65暂无昵称, createdTime=Mon Feb 22 08:05:41 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916336, encodeId=795c9163360c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:33:31 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916333, encodeId=dae6916333c7, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:31:51 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2021-01-13 ms2000001194856568

    #学习#好的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1219908, encodeId=048b1219908a6, content=太受用了！👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a18cf35bdfab43d496bab2a120649fae/3b4d7ff9e9364c3bae15229ee94a1b36.jpg, createdBy=9ea25397643, createdName=妙医生, createdTime=Mon May 16 08:26:30 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999194, encodeId=a6f89991948b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dd75194442, createdName=1472396fm10暂无昵称, createdTime=Tue Jul 13 20:37:46 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926282, encodeId=1afa92628250, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cf4759545, createdName=142f8dc2m65暂无昵称, createdTime=Mon Feb 22 08:05:41 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916336, encodeId=795c9163360c, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:33:31 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916333, encodeId=dae6916333c7, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0b5452553, createdName=ms2000001194856568, createdTime=Wed Jan 13 20:31:51 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2021-01-13 ms2000001194856568

    好

    0